Samyang Holdings 2026 Q1 Results: Return to Profit, Share Buyback Decision, and KFTC Fine Risk Coexist

Consolidated Q1 2026 revenue KRW 838.2B, operating profit KRW 29.1B, net profit KRW 34.8B (vs. full-year 2025 net loss of KRW 298.1B)
Board approved share buyback and cancellation in March 2026 (amount undisclosed)
75th AGM approved common dividend of KRW 3,500/share (total KRW 24.4B)
Subsidiary Samyang Foods fined KRW 130.2B by KFTC for unfair collusion (corrective order and installment payment underway)
Demerger of pharmaceutical/biotech division in Nov 2025, creating Samyang Biopharm (classified as discontinued operations)
Debt-to-equity ratio 93.6%, cash equivalents KRW 246B, stable financial position
Ongoing R&D in chemical segment (semiconductor materials) for future growth